Allocations
Nordic Capital Fund VI is to sell its majority shareholding in Nefab Packaging to the Nordgren/Pihl family, the original founders and currently co-owners of Nefab.
Since 2007, the company has grown its revenue and expanded its international presence. The strategy will remain the same under new ownership.
The Nordgren/Pihl family founded Nefab in 1949, and until 2007 was the majority owner of the company. Between 1996 and 2007, the company was listed on the Stockholm Stock Exchange. In 2007 the family and Nordic Capital joined forces to jointly acquire Nefab in a public-to-private transaction which delisted the company from
CMS Hasche Sigle has advised the Canadian power producer Northland Power on the acquisition of an 85 per cent majority in the offshore wind parks Nordsee One, Nordsee Two and "Nordsee Three" from the German utility RWE's daughter company RWEI Innogy.
The offshore wind farm "Nordsee One" is located approximately 40 kilometers north of the German island of Juist in the German Exclusive Economic Zone. From 2016 onwards, 54 turbines with a combined capacity of approximately 332 MW will be erected there. The turbines are expected to generate 1,300 gigawatt hours per year and will, from 2017 onwards, supply approximately
Ogier in Jersey assisted Kentz Corporation, the holding company of the Kentz engineering and construction group, in its acquisition by SNC-Lavalin Group for an overall purchase price of approximately GBP1.2 billion.
Kentz Corporation is a global engineering specialist solutions provider, with 15,500 employees operating in 36 countries worldwide. It has provided engineering, construction and technical support services to clients in the energy and resources sectors for more than 90 years.
SNC-Lavalin is an engineering and construction group and a major player in the ownership of infrastructure. The acquisition of Kentz enhances SNC-Lavalin's oil and gas capabilities, with end-to-end expertise for
Swander Pace Capital (SPC) has sold over-the-counter (OTC) products portfolio company Insight Pharmaceuticals to Prestige Brands Holdings for USD750 million.
The sale of Insight represents the firm’s second platform investment in the OTC industry.
“Today’s sale is the culmination of a successful five-year partnership to build a world-class OTC company,” says Mo Stout, managing director at SPC. “During our ownership, Insight grew sales from approximately USD80 million to more than USD200 million. We want to thank the management team at Insight for all of their hard work in creating significant value for the company’s stakeholders.”
“We are extremely proud
Enterprise Finance has acquired bridging lender West One Loans in a transaction funded by a combination of cash and equity.
Enterprise Finance is a specialist distributor focused on secured loans, bridging finance and commercial mortgages. It is backed by ISIS Equity Partners, which currently has GBP1.2bn of funds under management.
The two businesses, which are based in Borehamwood, Hertfordshire, are to be integrated in the near future with both companies moving to a new, larger headquarters in the local area.
The existing Enterprise Finance board, chaired by former wealth manager David Campbell and led by CEO Danny Waters, will
ECI Partners has held the final closing for its 10th buyout fund, ECI 10, at the hard cap of GBP500m.
ECI launched its latest fundraising in early April 2014 with a target fund size of GBP400m.
The fund was raised predominantly from its existing institutional investors, who have contributed 80 per cent of the capital, with an average increase on prior commitments of 33 per cent. There were also five new investors.
ECI 10 comprises a total of 25 institutional investors from the UK, US, Europe, the Middle East and Australia. They include pension funds, fund of funds, insurance
European Capital Debt Management (ECDM) has closed its new GBP100 million fund, European Capital UK SME Debt LP, a fund to provide debt finance in small and medium sized enterprises in the UK.
The fund will invest in businesses with a turnover of up to GBP100 million.
The British Business Bank is committing GBP50 million to the fund under the British Business Bank Investment Programme.
The remaining GBP50 million is being committed by European Capital Limited and its affiliates.
"We are delighted to announce the closing of our new fund, European Capital UK SME Debt LP," says
Private equity firm BV Investment Partners has completed the final closing for BV Investment Partners Fund VIII with USD487 million of committed capital, well above the fund's USD400 million target.
Vikrant Raina, managing partner of BV, says: "We would like to thank our limited partners for their support and endorsement of our investment strategy and team. We are well positioned to continue our successful strategy of partnering with entrepreneurs and management teams of innovative companies that can benefit from our operational expertise and financial resources. We are evaluating many exciting new high growth companies to add to the Fund VIII portfolio. I
Private equity firm Keensight Capital is in negotiations with Reed Elsevier for the sale of FircoSoft, a specialist in watch list filtering solutions.
The proposed transaction is expected to be concluded in the coming weeks, pending the completion of a consultation with the works council of FircoSoft.
Created in 1990 and based in Paris, FircoSoft provides software solutions which allow its clients to filter financial transactions against sanctions and watch lists in order to ensure compliance with existing regulations while meeting Know Your Customer (KYC) requirements.
In the context of the company’s spin-off from the Sword Group, Keensight
The Chiesi Group has launched a venture capital fund, Chiesi Ventures, via a collaboration with A M Pappas & Associates.
Chiesi Ventures will complement the strategic interest of the Chiesi Group in the area of rare diseases by investing in early stage opportunities and expanding the Chiesi network in the US among universities, venture capital investors, rare disease patient organisations and entrepreneurial companies developing treatments for rare diseases.
Chiesi Ventures will have offices in Boston (Massachusetts), Research Triangle Park (North Carolina) and Parma (Italy) and will focus on investment opportunities in the US and Europe. It will operate as an
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
